IPO Year: 2015
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $35.00 | Buy | TD Cowen |
3/28/2023 | $18.00 | Outperform | Evercore ISI |
9/29/2021 | $20.00 | Buy | Jefferies |
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's common stock on September 3, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.46, which is equal to the closing price o
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the upcoming Bradykinin Symposium in Berlin, Germany on September 6, 2024. Chris Morabito, M.D., Chief Medical Officer at Astria Therapeutics, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215." Kusumam Joseph, Senior Director of Medical Affairs at Astria Therapeutics, will present results from the
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York, New York. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310,
-- Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 -- -- Preclinical Results Support STAR-0310 as a Potential Best-in-Class OX40 Inhibitor -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "As we prepare for Phase 3 with initiation expected in Q1 2025, our vision for navenibart is to be the market-leading treatment for HAE, a large and growing market. Based on it
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215. "With STAR-0215's profile, our goal is to develop a therapy that allows patients to choose an approach that works best for their lives with the option of infrequent three- and six-month administration," said John Ruesch, Senior Vice President, Pharmaceutical Sciences and Technical Operations. "Our partnership with Ypsomed, a leading developer and manufacturer of injection systems, supports this goal through the planned develo
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will participate in a panel focused on hereditary angioedema (HAE) at the 2024 Wedbush PacGrow Healthcare Conference on August 14 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, "HAE Ya! The Changing Face of the HAE Therapeutic Landscape" on Wednesday, August 14 at 2:30pm ET. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and imm
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 29,150 shares of Astria's common stock on August 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.19, which is equal to the closing price of As
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 123,500 shares of Astria's common stock on July 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.25, which is equal to the closing price of As
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria's common stock on June 3, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to one employee entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.16, which is equal to the closing price of Astria
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6th at 10:00am ET in New York, NY. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and o
TD Cowen initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $35.00
Evercore ISI initiated coverage of Astria Therapeutics with a rating of Outperform and set a new price target of $18.00
Jefferies initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and lowers the price target from $29 to $25.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $16 price target.
Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $22 price target.
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate.
HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and lowers the price target from $18 to $16.
Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $17 to $22.
HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $18 price target.
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate a favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, and support both three- (Q3M) and six-month (Q6M) dosing regimens. Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initia
Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers ETAO International Co., Ltd. (NASDAQ:ETAO) shares shot up 111.5% to $0.3025. The company announced a reverse stock split. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) gained 74.3% to $1.7950 after the company announced plans to acquire The Social Proxy. TruGolf Holdings, Inc. (NASDAQ:TRUG) shares climbed 56% to $1.7938 after the company an
S-8 - Astria Therapeutics, Inc. (0001454789) (Filer)
10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)
ARS - Astria Therapeutics, Inc. (0001454789) (Filer)
DEFA14A - Astria Therapeutics, Inc. (0001454789) (Filer)
DEF 14A - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
424B5 - Astria Therapeutics, Inc. (0001454789) (Filer)
-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca
-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03
-- ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Phase 1a Results Support STAR-0215's Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days -- -- Ended 4Q 2022 with Cash, Cash Equivalents, and Short-term Investments of $226M, Expected Cash Runway Through H1 2025 -- -- Webcast Today at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for t
Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and full year 2022 financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.
-- Preliminary Results from Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Expected by Year-End 2022 -- -- Phase 1a Results Expected to Inform on STAR-0215's Profile to Prevent Attacks in Hereditary Angioedema -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We are on track to report preliminary results from our Phase 1a trial of STAR-0215 by the end of this year. The trial is assessing safety and
-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema -- -- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 -- -- Company to Host a Virtual R&D Day on September 30 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We are thrilled to announce that we have initiated dosing in our Phase 1a trial of STAR-0215 whic
-- On Track to File IND Application for STAR-0215 Mid-Year -- -- Initial Phase 1a Clinical Results Anticipated by Year End 2022 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "We are excited to advance STAR-0215 to the clinic this year with the planned initiation of our Phase 1a study," said Jill C. Milne, Ph.D., Chief Executive Officer of Astria. "STAR-0215 was created with a clear vision aim
-- STAR-0215, in Development to Treat HAE, on Track for Initial Phase 1 Clinical Results Expected by Year End 2022 -- -- New Preclinical Data on STAR-0215 Demonstrating High Potency and Extended Plasma Half-Life -- -- Findings on Burdens of Disease and Treatment in HAE Support Substantial Need to Decrease Patient Burden -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. "Our new company name, Astria, embodies our commitment to put patients first in all that we do. Astria originates fro
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), will report third quarter 2021 financial results before the Nasdaq Global Market open on Wednesday, November 10, 2021. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Conference Call Dial-In Information: Participant Toll-Free Dial-In Number: (877) 388-2733 Participant International Dial-In Number: (541) 797-2984 Passcode: 3606309 Please specify to the operator that you
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
3 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)